Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) Gross Margin (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Gross Margin for 6 consecutive years, with 80.62% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 13.0% year-over-year to 80.62%, compared with a TTM value of 79.81% through Dec 2025, down 56.0%, and an annual FY2025 reading of 79.81%, down 56.0% over the prior year.
  • Gross Margin was 80.62% for Q4 2025 at Treace Medical Concepts, up from 79.07% in the prior quarter.
  • Across five years, Gross Margin topped out at 83.94% in Q4 2021 and bottomed at 79.07% in Q3 2025.
  • Average Gross Margin over 5 years is 81.03%, with a median of 80.82% recorded in 2021.
  • The sharpest move saw Gross Margin soared 785bps in 2021, then crashed -207bps in 2022.
  • Year by year, Gross Margin stood at 83.94% in 2021, then decreased by -2bps to 81.87% in 2022, then decreased by 0bps to 81.56% in 2023, then dropped by -1bps to 80.74% in 2024, then dropped by 0bps to 80.62% in 2025.
  • Business Quant data shows Gross Margin for TMCI at 80.62% in Q4 2025, 79.07% in Q3 2025, and 79.67% in Q2 2025.